Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sound waves to save kidneys? new trial tests ultrasound for CKD

NCT ID NCT07339098

Disease control Sponsor: Anasonic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early study will test whether gentle ultrasound pulses applied to the kidneys can improve kidney function in 20 adults with chronic kidney disease (CKD). Participants will receive the ultrasound treatment three times a week for four weeks. Researchers will measure changes in kidney function and safety up to 12 weeks after treatment ends.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ultrasound stimulation device (NEFRONIX G-01)
What this could lead to
If it works, this could point toward a non-drug way to slow kidney decline in chronic kidney disease.
What could go wrong
This is a very small, early exploratory trial with only 20 people and no placebo group. The treatment may not improve kidney function at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants who have received sufficient explanation of the study and have voluntarily provided written informed consent. * Male and female adults aged 18 to 65 years at the time of consent. * Participants with chronic kidney disease, defined as an estimated glomerular filtration rate (eGFR) between 20 and 60 mL/min/1.73 m². * Participants who agree to use and maintain appropriate contraception throughout the study period. Exclusion Criteria: * Participants currently enrolled in another clinical study with an ongoing follow-up period. * Participants with heart failure. * Participants who have undergone reperfusion therapy for cardiovascular disease within the past year. * Participants with platelet or coagulation disorders, including those receiving antithrombotic therapy. * Participants with acute or chronic urinary tract infection. * Participants with polycystic kidneys. * Participants with anatomical kidney abnormalities (e.g., solitary kidney, horseshoe kidney, polycystic kidney disease) as determined by the investigator. * Participants with urinary tract obstruction. * Participants who have received a kidney transplant. * Participants with kidney or urinary tract stones. * Participants who have experienced acute kidney injury or changes in CKD stage within the past 3 months. * Participants with serum albumin \<3.0 g/dL and either 24-hour proteinuria ≥3.0 g/day or random urine protein/creatinine ratio ≥3.0 mg/mg. * Participants with uncontrolled hypertension (systolic blood pressure \>150 mmHg or diastolic blood pressure \>100 mmHg despite treatment with two or more antihypertensive medications). * Participants with liver dysfunction. * Participants receiving immunosuppressive therapy. * Participants with body mass index (BMI) \>35 kg/m² or body weight \<40 kg. * Participants with a history of severe illness, such as cancer or tuberculosis. * Participants with contact dermatitis or other significant skin sensitivities. * Participants with fever ≥40°C (104°F) measured via tympanic temperature. * Participants deemed unsuitable for participation in the study by the investigator for any other reason.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.